Pharmaceutical Care for Sotalol-induced QT Prolongation in Aged Patient with Heart Failure
10.6039/j.issn.1001-0408.2016.23.40
- VernacularTitle:索他洛尔致心力衰竭高龄患者QT间期延长的药学监护Δ
- Author:
Xiaodong LAI
;
Shan XU
;
Fei XIE
- Publication Type:Journal Article
- Keywords:
Heart failure;
Hepatic/renal insufficiency;
QT prolongation;
Sotalol;
Adverse drug reaction;
Pharmaceutical care
- From:
China Pharmacy
2016;27(23):3284-3287
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the role of clinical pharmacists participating in the prevention and treatment of sotalol-in-duced QT prolongation in aged patient with heart failure. METHODS:Clinical pharmacists participated in the treatment for a aged patient with heart failure,and assisted physicians to identify and assess the risk of sotalol-induced QT prolongation. According to the clinical symptoms and laboratory indexes,it was suggested to continue to use sotalol for antiarrhythmic,adjust the hepatoprotec-tive drug,given pharmaceutical care of ECG,electrolyte level monitoring,drug education and so on. RESULTS:Physicians adopt-ed the suggestions of clinical pharmacists to relive the illness without malignant arrhythmia and discharged after 11 d. CONCLU-SIONS:The patient with heart failure should be dominated by improving cardiac function and maintaining hemodynamic stability;combined with related guidelines and documentation,clinical pharmacists can assist physicians to identify the drug that induced QT prolongation,asses the risk of torsades de pointes ventricular tachycardia and other bad consequences,develop and optimize the regimen and strengthen pharmaceutical care to ensure the safe and effective treatment.
